Parameter | Estimate | SE | P value |
Month 12 | |||
Intercept | 16.4984 | 3.0543 | <0.0001 |
Baseline (letters) | 0.8549 | 0.0186 | <0.0001 |
Age (years) | −0.0939 | 0.0337 | 0.0053 |
Lesion size (DA) | −0.4527 | 0.0934 | <0.0001 |
Treatment (ranibizumab vs control) | 4.0367 | 0.5003 | <0.0001 |
Time (months) | 1.5749 | 0.5605 | 0.0050 |
Time (months)*Baseline (letters) | −0.0201 | 0.0033 | <0.0001 |
Time (months)*Age (years) | −0.0183 | 0.0063 | 0.0037 |
Time (months)*Treatment (ranibizumab vs control) | 1.4735 | 0.0895 | <0.0001 |
Time (months)*Lesion size (DA) | −0.0407 | 0.0175 | 0.0201 |
Month 24 | |||
Intercept | 18.6623 | 3.6461 | <0.0001 |
Baseline (letters) | 0.8184 | 0.0219 | <0.0001 |
Age (years) | −0.1217 | 0.0410 | 0.0030 |
Lesion size (DA) | −0.5110 | 0.1263 | <0.0001 |
Treatment (ranibizumab vs control) | 7.6340 | 0.6259 | <0.0001 |
Time (months) | 1.1429 | 0.2783 | <0.0001 |
Time (months)*Baseline (letters) | −0.0129 | 0.0018 | <0.0001 |
Time (months)*Age (years) | −0.0130 | 0.0032 | <0.0001 |
Time (months)*Treatment (ranibizumab vs control) | 0.7610 | 0.0494 | <0.0001 |
Time (months)*Lesion size (DA) | −0.0270 | 0.0102 | 0.0082 |
* in the table indicates the interaction between two terms in the analysis model
BCVA, best-corrected visual acuity; DA, disc area.